Geron Enterprise Value Over E B I T D A from 2010 to 2025

GERN Stock  USD 1.56  0.02  1.30%   
Geron Enterprise Value Over EBITDA yearly trend continues to be very stable with very little volatility. Enterprise Value Over EBITDA is likely to grow to -14.29 this year. During the period from 2010 to 2025, Geron Enterprise Value Over EBITDA quarterly data regression pattern had range of 941 and standard deviation of  233.46. View All Fundamentals
 
Enterprise Value Over EBITDA  
First Reported
2010-12-31
Previous Quarter
(15.04)
Current Value
(14.29)
Quarterly Volatility
233.45953073
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Geron financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Geron's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.4 M, Interest Expense of 19.4 M or Selling General Administrative of 153 M, as well as many indicators such as Price To Sales Ratio of 28.22, Dividend Yield of 0.0 or PTB Ratio of 8.57. Geron financial statements analysis is a perfect complement when working with Geron Valuation or Volatility modules.
  
Build AI portfolio with Geron Stock
Check out the analysis of Geron Correlation against competitors.
To learn how to invest in Geron Stock, please use our How to Invest in Geron guide.

Latest Geron's Enterprise Value Over E B I T D A Growth Pattern

Below is the plot of the Enterprise Value Over E B I T D A of Geron over the last few years. It is Geron's Enterprise Value Over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Geron's overall financial position and show how it may be relating to other accounts over time.
Enterprise Value Over E B I T D A10 Years Trend
Pretty Stable
   Enterprise Value Over E B I T D A   
       Timeline  

Geron Enterprise Value Over E B I T D A Regression Statistics

Arithmetic Mean50.44
Coefficient Of Variation462.87
Mean Deviation109.41
Median(6.15)
Standard Deviation233.46
Sample Variance54,503
Range941
R-Value(0.15)
Mean Square Error57,152
R-Squared0.02
Significance0.59
Slope(7.16)
Total Sum of Squares817,550

Geron Enterprise Value Over E B I T D A History

2025 -14.29
2024 -15.04
2023 -6.98
2022 -6.86
2021 -3.76
2020 -6.1
2019 -3.65

About Geron Financial Statements

Geron investors utilize fundamental indicators, such as Enterprise Value Over E B I T D A, to predict how Geron Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Enterprise Value Over EBITDA(15.04)(14.29)
When determining whether Geron offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Geron's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Geron Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Geron Stock:
Check out the analysis of Geron Correlation against competitors.
To learn how to invest in Geron Stock, please use our How to Invest in Geron guide.
You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Geron. If investors know Geron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Geron listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.20)
Revenue Per Share
0.176
Quarterly Revenue Growth
129.273
Return On Assets
(0.16)
Return On Equity
(0.45)
The market value of Geron is measured differently than its book value, which is the value of Geron that is recorded on the company's balance sheet. Investors also form their own opinion of Geron's value that differs from its market value or its book value, called intrinsic value, which is Geron's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Geron's market value can be influenced by many factors that don't directly affect Geron's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Geron's value and its price as these two are different measures arrived at by different means. Investors typically determine if Geron is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Geron's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.